Trial Profile
Phase I single-dose trial of FX-125L in volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Dec 2009
Price :
$35
*
At a glance
- Drugs FX 125L (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease; Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Funxional Therapeutics
- 21 Dec 2009 Results were presented at the 2009 Annual Meeting of the American College of Allergy, Asthma and Immunology.
- 13 Jul 2009 New trial record.